Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
复制标题
DOI：
10.7326/0003-4819-132-5-200003070-00005
复制
发表时间：
2000-03-07
影响因子：
39.2
通讯作者：
Kavanagh, JJ
中科院分区：
文献类型：
--
作者：
Vadhan-Raj, S;Verschraegen, CF;Kavanagh, JJ
背景：血小板减少症是癌症治疗中的一个重要问题。目的：评价重组人血小板生成素（rhTPO）治疗化疗所致严重血小板减少症的临床安全性及其改善作用。患者：29例妇科肿瘤患者。干预：在化疗前和第二周期卡铂治疗后给予重组人血小板生成素。测量方法：外周血计数和血小板输注。设计：I/II期临床队列研究设置：德克萨斯大学安德森癌症中心，休斯顿，德克萨斯州。结果：化疗后给予rhTPO可显著降低血小板减少的程度和持续时间，促进血小板恢复。在第2周期（卡铂加rhTPO）接受rhTPO最佳生物剂量（1.2 μ g/kg体重）的患者中，平均血小板计数最低点更高(44 × 10(9)个细胞/L和20 × 10(9)个细胞/L；P = 0.002)，血小板减少的持续时间较短（有血小板计数的天数）
Background: Thrombocytopenia is a significant problem in the treatment of cancer.Objective: To assess the clinical safety of therapy with recombinant human thrombopoietin (rhTPO) and its ability to ameliorate chemotherapy-induced severe thrombocytopenia. Patients: 29 patients with gynecologic cancer. Intervention: Recombinant human thrombopoietin was given before chemotherapy and after a second cycle of carboplatin therapy. Measurements: Peripheral blood counts and platelet transfusions.Design: Phase I/II clinical cohort studySetting: The University of Texas M.D. Anderson Cancer Center, Houston, Texas.Results: Administration of rhTPO after chemotherapy significantly reduced the degree and duration of thrombocytopenia and enhanced platelet recovery. In patients who received the optimal biological dose of rhTPO (1.2 mu g/kg of body weight) in cycle 2 (carboplatin plus rhTPO), the mean platelet count nadir was higher (44 x 10(9) cells/L and 20 x 10(9) cells/L; P = 0.002) and the duration of thrombocytopenia was shorter (days with a platelet count